Talk Topics this year cover:
- Importance of CDx for Biologics and Small Molecule Drugs – creating therapeutic and market value for patient-centric treatments
- Evolving CDx from animal models: From proof of concept (POC) to generating biomarker candidates; drug dosing; and response tracking
- Informatics for analyzing Big Data sets to develop CDx candidates
- Regulatory issues to be addressed during development
- Technologies to identify markers
We welcome researchers in biotechnology organizations ranging from start-up companies to leading-edge suppliers to non-profit institutions and encourage participation on the Program Committee as well as talk submissions. Attendees at this event typically range from Development to Post-Marketing Surveillance in biomarkers (development) and diagnostics (market offerings).
Expected Attendees include (see Attendee List):
- VPs in Translational Medicine and related functions
- Executive/Senior Directors
- Laboratory and Technology Directors
- Project Managers (technical, logistical, and transitioning projects to partners)
- Technology leaders and researchers (assays, platforms, informatics)
- Researchers in assays, diagnostics (basic, development, validation, execution)
- Allied VP, Executive/Senior Directors, Directors, and Associates in licensing and regulatory